EA202192903A1 - Кристаллическая форма ингибитора plk4 - Google Patents

Кристаллическая форма ингибитора plk4

Info

Publication number
EA202192903A1
EA202192903A1 EA202192903A EA202192903A EA202192903A1 EA 202192903 A1 EA202192903 A1 EA 202192903A1 EA 202192903 A EA202192903 A EA 202192903A EA 202192903 A EA202192903 A EA 202192903A EA 202192903 A1 EA202192903 A1 EA 202192903A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crystalline form
plk4 inhibitor
compound
plk4
inhibitor
Prior art date
Application number
EA202192903A
Other languages
English (en)
Inventor
Сзе-Ван Ли
Марк Роберт Брей
Original Assignee
Юниверсити Хелс Нетуорк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Хелс Нетуорк filed Critical Юниверсити Хелс Нетуорк
Publication of EA202192903A1 publication Critical patent/EA202192903A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Раскрыта кристаллическая форма S4 фумарата соединения (I), представленного следующей структурной формулойМолярное соотношение между соединением (I) и фумаровой кислотой составляет 1,0:1:0. Кристаллическая форма S4, характеризующаяся порошковой рентгеновской дифрактограммой, включает в себя пики при 6,6, 9,8, 16,3, 21,1, 28,7 и 30,2° 0,2 в 2.
EA202192903A 2019-04-24 2020-04-23 Кристаллическая форма ингибитора plk4 EA202192903A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962837858P 2019-04-24 2019-04-24
PCT/CA2020/050535 WO2020215155A1 (en) 2019-04-24 2020-04-23 Crystal form s4 of the plk4 inhibitor (lr,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarate

Publications (1)

Publication Number Publication Date
EA202192903A1 true EA202192903A1 (ru) 2022-02-09

Family

ID=72940551

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192903A EA202192903A1 (ru) 2019-04-24 2020-04-23 Кристаллическая форма ингибитора plk4

Country Status (15)

Country Link
US (1) US20220204494A1 (ru)
EP (1) EP3959209A4 (ru)
JP (1) JP2022530028A (ru)
KR (1) KR20220004102A (ru)
CN (1) CN113966330A (ru)
AU (1) AU2020264143A1 (ru)
BR (1) BR112021021106A2 (ru)
CA (1) CA3137191A1 (ru)
EA (1) EA202192903A1 (ru)
IL (1) IL287394A (ru)
MA (1) MA55767A (ru)
MX (1) MX2021012993A (ru)
SG (1) SG11202111003UA (ru)
TW (1) TW202104216A (ru)
WO (1) WO2020215155A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022240876A1 (en) 2021-05-11 2022-11-17 Oric Pharmaceuticals, Inc. Polo like kinase 4 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2756568C (en) 2009-04-06 2018-02-13 University Health Network Kinase inhibitors and method of treating cancer with same
LT2556071T (lt) 2010-04-06 2017-01-25 University Health Network Kinazės inhibitoriai ir jų panaudojimas vėžio gydymui
EP3057965B1 (en) * 2013-10-18 2019-01-02 University Health Network Salt and crystal forms of plk-4 inhibitor

Also Published As

Publication number Publication date
TW202104216A (zh) 2021-02-01
AU2020264143A1 (en) 2021-10-28
US20220204494A1 (en) 2022-06-30
CA3137191A1 (en) 2020-10-29
SG11202111003UA (en) 2021-11-29
MA55767A (fr) 2022-03-02
MX2021012993A (es) 2021-12-10
CN113966330A (zh) 2022-01-21
IL287394A (en) 2021-12-01
JP2022530028A (ja) 2022-06-27
WO2020215155A8 (en) 2020-11-26
BR112021021106A2 (pt) 2021-12-14
KR20220004102A (ko) 2022-01-11
EP3959209A4 (en) 2022-12-28
WO2020215155A1 (en) 2020-10-29
EP3959209A1 (en) 2022-03-02

Similar Documents

Publication Publication Date Title
PH12021550045A1 (en) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2022016515A (es) Nuevo inhibidor de la secrecion de acido y uso del mismo.
EA200601274A1 (ru) Новая кристаллическая форма iii агомелатина, способ её получения и фармацевтические композиции, которые её содержат
EA200300107A1 (ru) Кристаллические формы трет-бутиламиновой соли периндоприла
RS52197B (en) POTASSIUM IS A HIV INTEGRASE INHIBITOR
CY1112011T1 (el) Παραγωγα αζαδικυκλο (3.1.0) εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
MX2021000348A (es) 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo.
MX2021002382A (es) Sales y formas cristalinas de modulador alosterico positivo gabaa.
MX2022015551A (es) Metodos de sintesis para la preparacion de 4-(2-cloro-4-metoxi-5-m etilfenil)-n-[(1s)-2-ciclopropil-1-(3-fluoro-4-metilfenil)etil]-5 -metil-n-prop-2-inil-1,3-tiazol-2-amina.
MY183331A (en) Crystal form of phenylamino pyrimidine derivatives
EA202190880A1 (ru) Кристаллическая форма морфолинохиназолинового соединения, способ ее получения и ее применение
MX2021003427A (es) Nuevos oxadiazoles.
ZA202101487B (en) Novel compounds
MX2023010125A (es) Inhibidores del sarcomero cardiaco.
MX2022001958A (es) Sal.
MX2020011671A (es) Nuevo proceso para la preparacion de diamidas antranilicas.
EA202192903A1 (ru) Кристаллическая форма ингибитора plk4
MX2022007662A (es) Sintesis de compuestos para promover el crecimiento del cabello.
MX2021001904A (es) Formas solidas de benzoxaborol sustituido y composiciones de las mismas.
JOP20210072A1 (ar) ملح جديد لمثبط bcl-2، صورة بلورية ذات صلة، طريقة تحضيره وتركيبات صيدلية تحتوي عليه
WO2020127208A8 (en) Pharmaceutical process and intermediates
MX2020013729A (es) Compuestos de cianotriazol y usos de los mismos.
MX2022005201A (es) Formulaciones de naftalimida dimerica.
WO2020132471A8 (en) Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof
MX2021003430A (es) Nuevos oxadiazoles.